MURRAY, Utah, May 24, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 10:30am ET.
A live audio webcast of this presentation will be available on the Investor Relations section of R1’s website at r1rcm.com. A replay of the webcast will be available for 90 days following the live webcast.
About R1 RCM
R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: r1rcm.com.
Contacts
Investor Relations:
Evan Smith, CFA
(516) 743-5184
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Josh Blumenthal
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$14.07 |
| Daily Change: | -0.01 -0.07 |
| Daily Volume: | 4,509,468 |
| Market Cap: | US$5.940B |
August 07, 2024 August 01, 2024 June 17, 2024 May 08, 2024 February 27, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
